Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus.
K. Ikewaki, K. Mochizuki, Masafumi Iwasaki, R. Nishide +2 more
2002Metabolism: Clinical and Experimental43 citations
Semantic Scholar

